|1.||Zhanel, George G: 4 articles (07/2009 - 01/2002)|
|2.||Leclercq, R: 3 articles (01/2004 - 09/2001)|
|3.||Hoban, Daryl J: 3 articles (11/2003 - 01/2002)|
|4.||Van Bambeke, Françoise: 2 articles (11/2014 - 02/2008)|
|5.||Wierzbowski, Aleksandra: 2 articles (11/2003 - 01/2002)|
|6.||Georgopapadakou, Nafsika H: 1 article (10/2014)|
|7.||Penzien, Joseph B: 1 article (12/2009)|
|8.||Knickerbocker, Michael J: 1 article (12/2009)|
|9.||Finegan, Steven M: 1 article (12/2009)|
|10.||Li, Bryan: 1 article (12/2009)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/2009 - "Thus the pharmacokinetics of ketolides may help to explain their good activity against a wide range of respiratory tract infections, although pharmacokinetic/pharmacodynamic calculations based on plasma pharmacokinetics would indicate only minor activity against pathogens except streptococci. "
06/01/2004 - "Clinical efficacy of ketolides in the treatment of respiratory tract infections."
12/10/2009 - "Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections."
02/01/2008 - "Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections."
05/01/2005 - "Ketolides in the treatment of community-acquired respiratory tract infections: A review."
04/01/1999 - "The increased activity of ketolides against gram-positive bacteria suggests that further study of these agents for possible efficacy against infections caused by these bacteria is warranted."
08/15/2006 - "The in vivo efficacy of several C(12) ethyl ketolides was demonstrated in a mouse infection model with Streptococcus pneumoniae as pathogen."
04/01/2003 - "Telithromycin is the first of a new class of antibacterials, the ketolides, which have been developed specifically to provide effective treatment for these infections. "
10/01/2014 - "Optimer's solithromycin (OP-1068), acquired by Cempra (CEM-101), is currently in Phase III. Until this hepatotoxicity issue is resolved, ketolides are unlikely to replace established antibacterials for CAP, or lipoglycopeptides and oxazolidinones for gram-positive infections. "
01/01/2009 - "Besides enhancing killing of intracellular pathogens, the high concentrations of macrolides, azalides and ketolides in leukocytes have been associated with increased delivery of the antimicrobial agent to the site of infection. "
01/01/2004 - "Results of a number of clinical trials investigating 5-day therapy with oral cephalosporins, new quinolones or ketolides in acute (presumed) bacterial sinusitis in comparison with traditional 10-day treatment courses have been published demonstrating equivalent efficacy of 5-day and 10-day regimens. "
|4.||Legionnaires' Disease (Legionnaire's Disease)
03/01/2005 - "Ketolides: new antimicrobials for community-acquired pneumonia."
02/01/2008 - "Combined with an advantageous pharmacokinetic profile (good oral bioavailability and penetration in the respiratory tract tissues and fluids; prolonged half-life allowing for once-a-day administration), these antimicrobial properties make ketolides an attractive alternative for the treatment of severe respiratory tract infections such as pneumonia in areas with significant resistance to conventional macrolides. "
07/01/2009 - "To compare the probability of target attainment (PTA) for macrolides and ketolides against penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae in both serum and epithelial lining fluid (ELF) of patients with community-acquired pneumonia (CAP). "
01/12/2006 - "As a rule, oral antibiotic treatment with aminopenicillin, macrolides, fluorchinolones, ketolides or cephalosporins is applied, but decision-taking is also codetermined, for example, by whether an atypical pneumonia is suspected, or whether additional risk factors need to be taken into account."
11/01/2006 - "Macrolides, fluoroquinolones, doxycycline, and ketolides show a good intrinsic activity against intracellular pathogens which are responsible for a variable percentage of community-acquired pneumonia (CAP). "
|3.||Oxazolidinones (2 Oxazolidone)
|5.||Cephalosporins (Cephalosporin Antibiotics)
|7.||Anti-Bacterial Agents (Antibiotics)